FDA Approved: SKYRIZI — Supplemental Application (AbbVie Inc.)

View source ↗

Summary

FDA approved a supplemental application for SKYRIZI (risankizumab-rzaa) from AbbVie Inc. The action updates or expands the drug's regulatory status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease
• Plaque Psoriasis
• Psoriatic Arthritis

Drugs mentioned

• SKYRIZI (risankizumab-rzaa)

Snippet

SUPPL AP for SKYRIZI (RISANKIZUMAB-RZAA)